A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.
Christopher M TraudtBryan A ComstockRajan WadhawanDennis E MayockSherry E CourtneyTonya RobinsonKaashif A AhmadEllen Bendel-StenzelMariana BasergaEdmund F LaGammaL Corbin DowneyRaghavendra RaoNancy FahimAndrea LamplandIvan D Frantz IiiJanine Y KhanMichael WeissMaureen M GilmoreRobin K OhlsNishant SrinivasanJorge E PerezVictor McKayPhuong T VuJean LoweKarl KubanT Michael O'SheaAdam L HartmanPatrick J Heagertynull nullPublished in: The New England journal of medicine (2020)
High-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age. (Funded by the National Institute of Neurological Disorders and Stroke; PENUT ClinicalTrials.gov number, NCT01378273.).